Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | KIF11 | P52732 | 1/20 | 0.45 |
| ▸ | TGM2 | P21980 | 1/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | MMP3 | P08254 | 1/20 | 0.44 |
| ▸ | MMP7 | P09237 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL943656 | 1.00 | MMP2 (0.53) | MMP2CA12CA1EPHX2KDM4E | |
| SCHEMBL6495349 | 0.85 | SMN1; SMN2 (0.57) | SMN1; SMN2 | |
| SCHEMBL6495352 | 0.85 | SMN1; SMN2 (0.57) | SMN1; SMN2 | |
| SCHEMBL30007225 | 0.84 | NR1H4 (0.53) | EPHX2SMN1; SMN2NPC1RAB9ATRPV1 | |
| SCHEMBL26687939 | 0.84 | NR1H4 (0.53) | EPHX2SMN1; SMN2NPC1RAB9ATRPV1 | |
| SCHEMBL1259765 | 0.83 | MMP2 (0.56) | MMP2CA12CA1EPHX2NPC1 | |
| SCHEMBL9442663 | 0.83 | MMP2 (0.56) | MMP2CA12CA1EPHX2NPC1 | |
| SCHEMBL11072569 | 0.83 | MMP2 (0.56) | MMP2CA12CA1EPHX2NPC1 | |
| SCHEMBL6706715 | 0.82 | KDM4E (0.52) | KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL6706711 | 0.82 | KDM4E (0.52) | KDM4ESMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486302-B2 | Somatostatin receptor antagonist compounds and methods of using the same | CDRD VENTURES INC. (CA) | 2025-12-02 | — | — | US | disclosed |
| US-20220112242-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | CDRD VENTURES INC. (CA) | 2022-04-14 | — | — | US | disclosed |
| US-11279732-B2 | Somatostatin receptor antagonist compounds and methods of using the same | CDRD VENTURES INC. (CA) | 2022-03-22 | — | — | US | disclosed |
| EP-3941580-A1 | D-PEPTIDIC COMPOUNDS FOR VEGF | Reflexion Pharmaceuticals, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| US-20210061861-A1 | D-PEPTIDIC COMPOUNDS FOR VEGF | REFLEXION PHARMACEUTICALS, INC. | 2021-03-04 | — | — | US | disclosed |
| WO-2020198074-A1 | D-PEPTIDIC COMPOUNDS FOR VEGF | REFLEXION PHARMACEUTICALS, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| US-20190040102-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | CDRD VENTURES INC. (CA) | 2019-02-07 | — | — | US | disclosed |
| EP-3414259-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | CDRD Ventures Inc. (CA) | 2018-12-19 | — | — | EP | disclosed |
| US-9862837-B2 | Antifouling materials | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2018-01-09 | — | — | US | disclosed |
| WO-2017136943-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | CDRD VENTURES INC. (CA) | 2017-08-17 | — | — | WO | disclosed |
| EP-1680139-B1 | USE OF SOMATOSTATIN OR ONE OF THE ANALOGS THEREOF FOR PRODUCING A MEDICAMENT SERVING TO REGULATE THE OVARIAN FOLLICULAR RESERVE IN NON-MENOPAUSAL WOMEN | SOD CONSEILS RECH APPLIC (FR) | 2007-03-07 | — | — | EP | disclosed |
| EP-1680139-A2 | USE OF SOMATOSTATIN OR ONE OF THE ANALOGS THEREOF FOR PRODUCING A MEDICAMENT SERVING TO REGULATE THE OVARIAN FOLLICULAR RESERVE IN NON-MENOPAUSAL WOMEN | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2006-07-19 | — | — | EP | disclosed |
| EP-1372688-A4 | SOMATOSTATIN ANTAGONISTS | UNIV TULANE (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005034989-A2 | USE OF SOMATOSTATIN OR ONE OF THE ANALOGS THEREOF FOR PRODUCING A MEDICAMENT SERVING TO REGULATE THE OVARIAN FOLLICULAR RESERVE IN NON-MENOPAUSAL WOMEN | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (I.N.S.E.R.N) (FR) | 2005-04-21 | — | — | WO | disclosed |
| EP-1522311-A1 | Use of somatostatin or analogs thereof for the preparation of a medicament for the regulation of ovarian follicles reserve by non menopausaled women | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2005-04-13 | — | — | EP | disclosed |
| US-20040181032-A1 | Somatostatin antagonists | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND | 2004-09-16 | — | — | US | disclosed |
| EP-1372688-A2 | SOMATOSTATIN ANTAGONISTS | The Administrators of The Tulane Educational Fund (US) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002072602-A2 | SOMATOSTATIN ANTAGONISTS | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2002-09-19 | — | — | WO | disclosed |
| EP-0773956-A1 | PURIFIED FORM OF STREPTOGRAMINES, PREPARATION OF SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Aventis Pharma S.A. (FR) | 1997-05-21 | — | — | EP | disclosed |
| WO-1996004298-A1 | PURIFIED FORM OF STREPTOGRAMINES, PREPARATION OF SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | RHONE-POULENC RORER S.A. (FR) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061861-A1 | D-PEPTIDIC COMPOUNDS FOR VEGF | VEGFA, KDR, FLT1 | MMP2 1230/4885CA12 2749/4885CA1 4481/4885 |
| US-20040181032-A1 | Somatostatin antagonists | SSTR4, SSTR1, SSTR5 | MMP2 4169/4885CA12 2082/4885CA1 1215/4885 |
| US-12486302-B2 | Somatostatin receptor antagonist compounds and methods of using the same | GPR119, SSTR5, SSTR2 | MMP2 3213/4885CA12 635/4885CA1 330/4885 |
| US-11279732-B2 | Somatostatin receptor antagonist compounds and methods of using the same | GPR119, SSTR5, SSTR2 | MMP2 3203/4885CA12 662/4885CA1 325/4885 |
| US-20220112242-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | GPR119, SSTR5, SSTR2 | MMP2 3213/4885CA12 635/4885CA1 330/4885 |
| US-20190040102-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | GPR119, SSTR5, SSTR2 | MMP2 3203/4885CA12 662/4885CA1 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.